On the stock market since 1996, it operates in the world of health and science. It has 689 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
An average decline of 29% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
The stock trades 31% below its peak. The market has trimmed its expectations for the company.
The company sells $141.4M a year; the problem isn’t sales — it’s costs running above that number.
Over the last 12 months, company executives reported 37 buys and 9 sells. Management buying with its own money is usually read as a good sign.
The average analyst price target is $13.00 — 48% above today’s price.
A loss of $26.0M against $141.4M in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, LNDC sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: LNDC is a small company that closed last year at a loss. The road back to profit runs through spending discipline.